Cardinal Health is a distributor of pharmaceuticals, a global manufacturer, and distributor of medical and laboratory products, and a provider of performance, and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 46,500 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns RemainNovember 4th 2022
Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Adding Drug Costs to the Clinical Support EquationJune 23rd 2022
Amy Valley, PharmD, vice president of clinical strategy and technology solutions, Cardinal Health Specialty Solutions, discusses the Decision Path, a clinical support tool designed to inform oncology providers about drug costs along with clinical information, all embedded into the electronic health record workflow.
Cardinal Health’s Aklilu Tedla on CAR T-Cell Administration Outside of the HospitalJune 8th 2022
Moving chimeric antigen receptor (CAR) T-cell therapies outside of the hospital will bring training and safety challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Cardinal Health’s Aklilu Tedla Discusses Logistics of Allogeneic CAR T-Cell TherapiesMay 31st 2022
Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Dr Sonia Oskouei Highlights the Need to Align Incentives to Promote Use of BiosimilarsMay 27th 2022
Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab BiosimilarsMay 16th 2022
While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report FindsFebruary 8th 2022
Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Stronger Community Connections, Fewer Barriers Are Keys to Better TrialsDecember 19th 2021
Bruce A. Feinberg, DO, of Cardinal Health Specialty Solutions, leads a panel discussion on how far randomized clinical trials have come, how they could be better, and how using real-world evidence could make research more representative of the population.
What's Next After OCM? Possibly a Gap and Something Mandatory, Experts PredictSeptember 25th 2021
With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.